SCHEMBL463622

SCHEMBL463622

CCOC(=O)Nc1ccc(C(F)(F)F)cc1I

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.54
CYP2C9 P11712 2/20 0.54
CYP2C19 P33261 2/20 0.54
KCNQ2 O43526 4/20 0.53
KCNQ3 O43525 3/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
KCNQ4 P56696 2/20 0.49
KCNQ5 Q9NR82 2/20 0.49
ALDH1A1 P00352 4/20 0.48
GAA P10253 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
POLB P06746 1/20 0.46
GPR35 Q9HC97 1/20 0.45
THRB P10828 1/20 0.44
HPGD P15428 2/20 0.43
MAPT P10636 2/20 0.43
NPSR1 Q6W5P4 1/20 0.42
KDM4E B2RXH2 2/20 0.42
KMT2A Q03164 2/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6286603 0.89 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL4826498 0.87 MAPT (0.55) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL4818327 0.85 CYP1A2 (0.52) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL3888607 0.82 PLK1 (0.55) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL404929 0.82 CYP1A2 (0.73) CYP1A2CYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL2539102 0.81 CYP1A2 (0.51) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL439922 0.80 NLRP3 (0.52) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL29646429 0.80 NLRP3 (0.52) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL2070682 0.78 CYP1A2 (0.58) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3
SCHEMBL20780339 0.78 KCNQ2 (0.48) CYP1A2CYP2C9CYP2C19KCNQ2KCNQ3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8889674-B2 Piperidine and pyrrolidine derivatives having NPY Y5 receptor antagonism SHIONOGI & CO., LTD. (JP) 2014-11-18 US disclosed
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE ALCON RESEARCH, LTD (US) 2012-03-15 US disclosed
US-20110319412-A1 PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM SHIONOGI & CO., LTD. (JP) 2011-12-29 US disclosed
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2011-10-20 US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE KALYPSYS, INC. (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100120741-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 CYP1A2 2609/4885CYP2C9 2484/4885CYP2C19 1732/4885
US-20120065187-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 CYP1A2 2609/4885CYP2C9 2484/4885CYP2C19 1732/4885
US-20110257137-A1 HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE HRH4, HRH3, HRH2 CYP1A2 2609/4885CYP2C9 2484/4885CYP2C19 1732/4885
US-20110319412-A1 PIPERIDINE AND PYRROLIDINE DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISM NPY5R, NPY1R, NPY2R CYP1A2 2467/4885CYP2C9 2232/4885CYP2C19 2168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.